Skip to main content

Table 3 Proposed list of domains and domain items for round 1 of the eDelphi questionnaire

From: TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries

Domains Domain items
Demographics Social history
Marital history
Past AE treatments Previous topical treatments for AE
Previous day hospital care treatments for AE
Previous hospitalisation for AE
Previous structured education programme for AE
Current AE treatments Topical treatments
Allergy test results Delayed contact hypersensitivity patch test
Atopy patch test
Double-blind, placebo-controlled food challenge
Skin-prick testing to foods or aeroallergens
Chronic (inflammatory) comorbidities Inflammatory bowel disease
Rheumatoid arthritis
Diabetes mellitus
Smoking/alcohol/recreational drug history Smoking history
Alcohol intake
Recreational drug history (soft drugs)
Current concomitant medication (i.e. other than specific AE medication Antihistamines, oral or topical
Topical antibiotics
Oral antibiotics
Allergic rhinoconjunctivitis medication
Asthma medication
Baseline physical examination Fitzpatrick skin type
Weight and height for BMI calculation
Blood pressure
Body temperature
Chest (lung) auscultation
Heart auscultation
Lymph node palpation (axillary and inguinal)
Skin examination
Baseline physician and patient reported domains Physician-assessed clinical signs, e.g. EASI or SCORAD score
Investigator/physician global assessment, e.g. IGA
Patient-reported symptoms, e.g. POEM, itch or sleep score
Patient global assessment, e.g. PGA
Generic quality of life score
Dermatology-specific quality of life score
AE-specific quality of life score
Patient-reported satisfaction with AE care received
Baseline investigations and assessments Blood testing for past/current tuberculosis
Chest radiograph
Hepatitis B status
Hepatitis C status
Human immunodeficiency virus (HIV) status
Varicella zoster virus (VZV) immune status
Pregnancy
Monitoring P3NP in case of methotrexate use in adults
Evaluating TPMT level prior to azathioprine use
Collection of medical photographs to monitor disease extent
Baseline biorepository samples Collection of blood for biomarkers, e.g. TARC
Collection of DNA (blood or saliva) for filaggrin analysis
Collection of biomaterials, e.g. DNA, PBMC or skin biopsy, for a biorepository
Baseline management Reasons for choosing specific treatment (systemic or phototherapy)
Routine recording of relative contraindication(s) for selected treatment
Follow-up general questions Minimum follow-up frequency for registry data entry, once stable therapeutic dose has been reached:
 A. 2 months
 B. 3 months
 C. 4 months
 D. 5 months
 E. 6 months
Minimum follow-up frequency for registry data entry, after stopping photo- or systematic therapy:
 A. 3 months
 B. 6 months
 C. Annually
 D. No follow-up
Follow-up physical examination Weight and height for BMI calculation
Blood pressure
Body temperature
Chest (lung) auscultation
Heart auscultation
Lymph node palpation (axillary and inguinal)
Skin examination
Follow-up physician- and patient-reported domains Physician-assessed clinical signs, e.g. EASI or SCORAD score
Investigator/physician global assessment, e.g. IGA
Patient-reported symptoms, e.g. POEM, itch or sleep score
Patient global assessment, e.g. PGA
Generic quality of life score
Dermatology-specific quality of life score
AE-specific quality of life score
Reporting of disease control, e.g. flares, fully controlled weeks, by physician
Reporting of disease control, e.g. flares, fully controlled weeks, by patient
Adherence to treatment between appointments
Patient-reported satisfaction with AE care received
Follow-up investigations and assessments Minimum frequency of safety investigations:
 A. 6 weeks
 B. 8 weeks
 C. 10 weeks
 D. 12 weeks
 E. 14 weeks
 F. 16 weeks
Collection of medical photographs to monitor disease extent
Follow-up biorepository samples Collection of blood for biomarkers, e.g. TARC
Collection of biomaterials, e.g. DNA, PBMC or skin biopsy, for a biorepository
  1. AE atopic eczema, BMI Body Mass Index, DNA deoxyribonucleic acid, EASI Eczema Area and Severity Index, HIV Human Immunodeficiency Virus, IGA Investigator Global Assessment, P3NP procollagen type III N-terminal peptide, PBMC peripheral blood mononuclear cell, PGA Patient Global Assessment, POEM Patient-oriented Eczema Measure, SCORAD SCORing Atopic Dermatitis Index, TARC thymus and activation-regulated chemokine, VZV varicella zoster virus